Latest Breaking News On - Common terminology criteria - Page 9 : comparemela.com

FOLFOX Produces Varying Toxicity Profile vs Chemoradiation in Rectal Cancer

Lower rates of diarrhea and overall bowel dysfunction were reported with the use of neoadjuvant fluorouracil and oxaliplatin vs neoadjuvant pelvic chemoradiation with fluorouracil (5FCURT) in patients with locally advanced rectal cancer. However, lower rates of other toxicities were reported in patients treated with 5FCURT.

United statesTrial alliancePatient reported outcomesCommon terminology criteriaAdverse eventsClinical oncology annual meeting

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin s Lymphoma (NHL)

ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved CD19 autologous CAR T therapy Plan to transition ADI-001 program into potentially pivotal Phase 2 study in post-CAR T large B-cell lymphoma (LBCL) patients in first half of 2024 Clinical update from additional post-CAR T LBCL patients expected in second half of 2024 Company to host investor web

United statesAdicet bioChen schorFrancesco galimiAmerican society for transplantationCompany twitterAdicet bio incExchange commissionInternational prognostic indexSenior vice presidentChief medical officerChief executive officerEfficacy dataEfficacy evaluable patientsCommon terminology criteriaAdverse events

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin s Lymphoma (NHL) | National Business

REDWOOD CITY, Calif. & BOSTON (BUSINESS WIRE) Jun 26, 2023

United statesFrancesco galimiChen schorContactsanne bowdidgeAdicet bioAmerican society for transplantationCompany twitterInternational prognostic indexExchange commissionAdicet bio incStern investor relations incSenior vice presidentChief medical officerChief executive officerEfficacy dataEfficacy evaluable patients

Anti–LAG-3/PD-1 Combination Under Investigation as Adjuvant Therapy in High-Risk Melanoma

Anti–LAG-3/PD-1 Combination Under Investigation as Adjuvant Therapy in High-Risk Melanoma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesTimothyj panellaUniversity of tennessee medical center at knoxvilleTennessee medical centerCommon terminology criteriaAdverse eventsNorth america

Adicet Bio (ACET) Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin s Lymphoma

Adicet Bio (ACET) Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin s Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrancesco galimiChen schorAdicet bioAdicet bio incAmerican society for transplantationInternational prognostic indexSenior vice presidentChief medical officerChief executive officerEfficacy dataEfficacy evaluable patientsCommon terminology criteriaAdverse eventsAmerican societyCellular therapy